MedTrace Logo

Tumor Growth Rate (TGR) Predicts Clinical Outcomes for Advanced Non-small Cell Lung Cancer Undergoing Immunotherapy.

NCT04722406 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2021-03-17

No results posted yet for this study

Summary

We hypothesized that TGR could serve as an early predictor of outcomes for aNSCLC patients undergoing immune checkpoint inhibitors (ICIs). A retrospective analysis was conducted to investigate the association of TGR with response and long-term survival of aNSCLC patients undergoing ICI therapy.

Conditions

Interventions

OTHER

This item is not applicable to our observational study.

This item is not applicable to our observational study.

Sponsors & Collaborators

  • Guangdong Provincial Hospital of Traditional Chinese Medicine

    collaborator OTHER

  • Shanghai Chest Hospital

    collaborator OTHER

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Shaodong Hong, MD · Sun Yat-sen University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-15
Primary Completion
2021-07-01
Completion
2021-08-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04722406 on ClinicalTrials.gov